References
- Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6(10):803–812.
- Mitchell EP, Perez-Soler R, Van Cutsem E, Lacouture ME. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. Oncology. 2007;21(11 Suppl 5):4–9.
- Joshi S, Ortiz S, Witherspoon JN, Rademaker A, West DP, Anderson R, et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer. 2010;116(16):3916–3923.
- McGill DJ, Hutchison C, McKenzie E, McSherry E, Mackay IR. A randomised, split-face comparison of facial hair removal with the alexandrite laser and the intense pulsed light system. Lasers Surg Med. 2007;39(10):767–772.
- Balagula Y, Rosen ST, Lacouture ME. The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies. J Am Acad Dermatol. 2011;65(3):624–635.
- Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Supp Care Cancer. 2011;19(8):1079–1095.
- Solomon BM1, Jatoi A. Epidermal growth factor receptor (EGFR) inhibitor-induced rash: a consecutive patient series that illustrates the need for rigorous palliative trials. J Palliat Med. 2011;14(2):153–156.
- Brauer JA, Gordon Spratt EA, Geronemus RG. Laser therapy in the treatment of connective tissue diseases: a review. Dermatol Surg. 2014;c40(1):1–13.
- Kong H, Fine H, Stern J, Turner M. Cutaneous pigmentation after photosensitivity induced by vandetanib therapy. Arch Dermatol. 2009;145(8):923–925.